{"id":"W4207000124","doi":"10.1093/ecco-jcc/jjab232.122","title":"DOP83 Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn’s Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","year":2022,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Maintenance therapy; Crohn's disease; Placebo; Biomarker; Clinical trial; Calprotectin; C-reactive protein; Disease; Inflammatory bowel disease; Chemotherapy; Inflammation; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003162765,0.0005715188,0.001666299,0.0002058439,0.0002282813,0.0007550914,0.0003541781,0.0008333165,0.002167782],"category_scores_gemma":[0.001343633,0.0002749117,0.001394061,0.0002681802,0.0003850523,0.000375681,0.0003471518,0.001134996,0.0003766273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003118562,"about_ca_system_score_gemma":0.0006200183,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003433794,"about_ca_topic_score_gemma":0.00106306,"domain_scores_codex":[0.9987858,0.0008119377,0.00008005119,0.00009747615,0.0001219905,0.0001028023],"domain_scores_gemma":[0.9987061,0.0003514828,0.0003981079,0.0001042594,0.0001457783,0.000294274],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8946381,0.007515007,0.01805014,0.0009035592,0.00257951,0.00009396455,0.0001183419,0.000416367,0.01389302,0.0001297283,0.003118247,0.058544],"study_design_scores_gemma":[0.5403917,0.3294987,0.1136771,0.0001758112,0.002702423,0.0002187486,0.0001078895,0.0008262253,0.004519545,0.0002252132,0.007601624,0.00005501844],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893627,0.005552439,0.0002324418,0.0004719739,0.0001121394,0.0007477147,0.001144554,0.00004009897,0.002335976],"genre_scores_gemma":[0.994324,0.001240772,0.0007322701,0.0004984133,0.0001705869,0.000671215,0.001362203,0.000008615381,0.0009920056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003162765,"threshold_uncertainty_score":0.01672655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009744331571415969,"score_gpt":0.2848104197119485,"score_spread":0.2750660881405326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}